Abatacept in B7-1-positive proteinuric kidney disease.

Abstract

Abatacept (cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion protein [CTLA-4-Ig]) is a costimulatory inhibitor that targets B7-1 (CD80). The present report describes five patients who had focal segmental glomerulosclerosis (FSGS) (four with recurrent FSGS after transplantation and one with primary FSGS) and proteinuria with B7-1 immunostaining of podocytes in kidney-biopsy specimens. Abatacept induced partial or complete remissions of proteinuria in these patients, suggesting that B7-1 may be a useful biomarker for the treatment of some glomerulopathies. Our data indicate that abatacept may stabilize β1-integrin activation in podocytes and reduce proteinuria in patients with B7-1-positive glomerular disease.

• Authors: Chih-Chuan Yu, Alessia Fornoni, Astrid Weins, Samy Hakroush, Dony Maiguel, Junichiro Sageshima, Linda Chen, Gaetano Ciancio, Mohd Hafeez Faridi, Daniel Behr, Kirk N Campbell, Jer-Ming Chang, Hung-Chun Chen, Jun Oh, Christian Faul, M Amin Arnaout, Paolo Fiorina, Vineet Gupta, Anna Greka, George W Burke 3rd, Peter Mundel
• Journal: The New England journal of medicine (N Engl J Med) Vol. 369 Issue 25 Pg. 2416-23 (Dec 19 2013) ISSN: 1533-4406 [Electronic] United States
• PMID: 24206430 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)

Chemical References

• B7-1 Antigen
• Biomarkers
• Immunoconjugates
• Abatacept

Topics

• Abatacept
• Adolescent
• Adult
• B7-1 Antigen (antagonists & inhibitors, metabolism)
• Biomarkers (metabolism)
• Child
• Female
• Glomerulosclerosis, Focal Segmental (complications, drug therapy, immunology)
• Humans
• Immunoconjugates (pharmacology, therapeutic use)
• Male
• Podocytes (drug effects, metabolism)
• Proteinuria (drug therapy, etiology)
• Young Adult